Garrett M Brodeur

List of Publications by Year
in descending order

127 papers	17,684 citations	31976 53 h-index	17105 122 g-index
130 all docs	130 docs citations	130 times ranked	11929 citing authors

#	Article	IF	Citations
1	Neuroblastoma: biological insights into a clinical enigma. Nature Reviews Cancer, 2003, 3, 203-216.	28.4	1,871
2	Association of Multiple Copies of the N-mycOncogene with Rapid Progression of Neuroblastomas. New England Journal of Medicine, 1985, 313, 1111-1116.	27.0	1,853
3	Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid. New England Journal of Medicine, 1999, 341, 1165-1173.	27.0	1,722
4	The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report. Journal of Clinical Oncology, 2009, 27, 289-297.	1.6	1,540
5	Identification of ALK as a major familial neuroblastoma predisposition gene. Nature, 2008, 455, 930-935.	27.8	1,207
6	The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report. Journal of Clinical Oncology, 2009, 27, 298-303.	1.6	869
7	Association between High Levels of Expression of the TRK Gene and Favorable Outcome in Human Neuroblastoma. New England Journal of Medicine, 1993, 328, 847-854.	27.0	639
8	Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. New England Journal of Medicine, 2005, 353, 2243-2253.	27.0	495
9	A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene. Molecular Cancer Research, 2008, 6, 735-742.	3.4	298
10	Trk Receptor Expression and Inhibition in Neuroblastomas. Clinical Cancer Research, 2009, 15, 3244-3250.	7.0	258
11	Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene, 1999, 18, 4948-4957.	5.9	228
12	Mechanisms of neuroblastoma regression. Nature Reviews Clinical Oncology, 2014, 11, 704-713.	27.6	228
13	Biologic Factors Determine Prognosis in Infants With Stage IV Neuroblastoma: A Prospective Childrenâ€™s Cancer Group Study. Journal of Clinical Oncology, 2000, 18, 1260-1268.	1.6	212
14	Biology and Genetics of Human Neuroblastomas. The American Journal of Pediatric Hematology/oncology, 1997, 19, 93-101.	1.3	205
15	Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: Clinical outcome and antineuronal antibodies?a report from the children's cancer group study. Medical and Pediatric Oncology, 2001, 36, 612-622.	1.0	203
16	Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Research, 2002, 62, 6462-6.	0.9	182
17	Integrative Genomics Identifies Distinct Molecular Classes of Neuroblastoma and Shows That Multiple Genes Are Targeted by Regional Alterations in DNA Copy Number. Cancer Research, 2006, 66, 6050-6062.	0.9	178
18	Molecular biology and genetics of human neuroblastoma. Cancer Genetics and Cytogenetics, 1989, 41, 153-174.	1.0	176

#	Article	IF	Citations
19	Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene, 2000, 19, 4604-4610.	5.9	169
20	Retinoblastoma and Neuroblastoma Predisposition and Surveillance. Clinical Cancer Research, 2017, 23, e98-e106.	7.0	166
21	CHD5 , a Tumor Suppressor Gene Deleted From 1p36.31 in Neuroblastomas. Journal of the National Cancer Institute, 2008, 100, 940-949.	6.3	164
22	Spontaneous regression of neuroblastoma. Cell and Tissue Research, 2018, 372, 277-286.	2.9	149
23	Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene, 2005, 24, 2684-2694.	5.9	147
24	Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Childrenâ€™s Cancer Group Study. Journal of Clinical Oncology, 2000, 18, 1888-1899.	1.6	146
25	CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene, 2003, 22, 1002-1011.	5.9	145
26	Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome. Clinical Cancer Research, 2017, 23, e62-e67.	7.0	139
27	Hyperdiploidy Plus Nonamplified MYCN Confers a Favorable Prognosis in Children 12 to 18 Months Old With Disseminated Neuroblastoma: A Pediatric Oncology Group Study. Journal of Clinical Oncology, 2005, 23, 6466-6473.	1.6	135
28	Neuroblastoma: Effect of genetic factors on prognosis and treatment. Cancer, 1992, 70, 1685-1694.	4.1	134
29	Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors. Cancer, 2001, 92, 2699-2708.	4.1	132
30	Pediatric Cancer Predisposition and Surveillance: An Overview, and a Tribute to Alfred G. Knudson Jr. Clinical Cancer Research, 2017, 23, e1-e5.	7.0	130
31	Molecular Basis of Clinical Heterogeneity in Neuroblastoma. Journal of Pediatric Hematology/Oncology, 1992, 14, 111-116.	0.6	127
32	Expression of TrkA, TrkB and TrkC in human neuroblastomas. Journal of Neuro-Oncology, 1997, 31, 49-56.	2.9	127
33	Proliferation of Human Neuroblastomas Mediated by the Epidermal Growth Factor Receptor. Cancer Research, 2005, 65, 9868-9875.	0.9	122
34	Expression of the Neurotrophin Receptor TrkB Is Associated With Unfavorable Outcome in Wilmsâ€™ Tumor. Journal of Clinical Oncology, 2001, 19, 689-696.	1.6	99
35	Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTRK2). Genomics, 1995, 25, 538-546.	2.9	88
36	Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells. Oncogene, 2000, 19, 2043-2051.	5.9	86

#	Article	IF	Citations
37	Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Research, 2002, 62, 1802-8.	0.9	81
38	Role of CHD5 in Human Cancers: 10 Years Later. Cancer Research, 2014, 74, 652-658.	0.9	77
39	Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemotherapy and Pharmacology, 2011, 68, 1057-1065.	2.3	76
40	Outcomes of Children With Intermediate-Risk Neuroblastoma After Treatment Stratified by MYCN Status and Tumor Cell Ploidy. Journal of Clinical Oncology, 2005, 23, 8819-8827.	1.6	74
41	CHD5 is required for spermiogenesis and chromatin condensation. Mechanisms of Development, 2014, 131, 35-46.	1.7	69
42	Clinical implications of oncogene activation in human neuroblastomas. Cancer, 1986, 58, 541-545.	4.1	68
43	Clinical Significance of MYCN Amplification and Ploidy in Favorable-Stage Neuroblastoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2008, 26, 913-918.	1.6	67
44	Preferential amplification of the paternal allele of the Nâ€“myc gene in human neuroblastomas. Nature Genetics, 1993, 4, 191-194.	21.4	65
45	Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. Cancer Research, 2002, 62, 6651-8.	0.9	65
46	Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Medical and Pediatric Oncology, 2001, 36, 32-36.	1.0	63
47	Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model. Cancer Letters, 2016, 372, 179-186.	7.2	63
48	Resistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Medical and Pediatric Oncology, 2000, 35, 603-607.	1.0	61
49	Mechanisms of CHD5 Inactivation in Neuroblastomas. Clinical Cancer Research, 2012, 18, 1588-1597.	7.0	60
50	A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma. Clinical Cancer Research, 2012, 18, 2012-2023.	7.0	59
51	Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. Cancer, 2016, 122, 935-945.	4.1	58
52	Coâ€amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma. Genes Chromosomes and Cancer, 1995, 14, 196-203.	2.8	56
53	Lestaurtinib Enhances the Antitumor Efficacy of Chemotherapy in Murine Xenograft Models of Neuroblastoma. Clinical Cancer Research, 2010, 16, 1478-1485.	7.0	56
54	The â€œneuroâ€•of neuroblastoma: <scp>N</scp>euroblastoma as a neurodevelopmental disorder. Annals of Neurology, 2016, 80, 13-23.	5.3	54

#	Article	IF	Citations
55	Correlation between morphologic and other prognostic markers of neuroblastoma a study of histologic grade, DNA index, N-myc gene copy number, and lactic dehydrogenase in patients in the pediatric oncology group. Cancer, 1993, 71, 3173-3181.	4.1	53
56	Epigenetic silencing of CHD5, a novel tumorâ€suppressor gene, occurs in early colorectal cancer stages. Cancer, 2014, 120, 172-180.	4.1	51
57	Novel regions of chromosomal loss in familial neuroblastoma by comparative genomic hybridization. , 1997, 19, 176-184.		48
58	Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma. Medical and Pediatric Oncology, 2001, 36, 24-27.	1.0	48
59	Human neuroblastoma cell lines that express N-myc without gene amplification. Cancer, 1993, 72, 3346-3354.	4.1	43
60	Therapeutic targets for neuroblastomas. Expert Opinion on Therapeutic Targets, 2014, 18, 277-292.	3.4	43
61	Familial neuroblastoma: A three-generation pedigree and a further association with Hirschsprung disease. , 1997, 28, 1-5.		40
62	High-Resolution Mapping of a 130-kb Core Region of theMYCNAmplicon in Neuroblastomas. Genomics, 1996, 32, 97-103.	2.9	39
63	Deletion of 11q23 is a frequent event in the evolution ofMYCN single-copy high-risk neuroblastomas. Medical and Pediatric Oncology, 2000, 35, 544-546.	1.0	37
64	Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy. Biomaterials, 2015, 51, 22-29.	11.4	36
65	The tumour suppressor CHD5 forms a NuRD-type chromatin remodelling complex. Biochemical Journal, 2015, 468, 345-352.	3.7	36
66	Neuroblastoma -Clinical Applications of Molecular Parameters. Brain Pathology, 1990, 1, 47-54.	4.1	34
67	Clinical significance of NTRK family gene expression in neuroblastomas. Pediatric Blood and Cancer, 2012, 59, 226-232.	1.5	33
68	Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma. Cancer Letters, 2015, 360, 205-212.	7.2	32
69	TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts. Cancer Chemotherapy and Pharmacology, 2015, 75, 131-141.	2.3	32
70	Diagnosis of Beckwithâ€“Wiedemann syndrome in children presenting with Wilms tumor. Pediatric Blood and Cancer, 2018, 65, e27296.	1.5	32
71	Expression of neurotrophin receptor TrkA inhibits angiogenesis in neuroblastoma. Medical and Pediatric Oncology, 2000, 35, 569-572.	1.0	31
72	Relative Quantitative RT-PCR Protocol for TrkB Expression in Neuroblastoma Using GAPD as an Internal Control. BioTechniques, 2000, 28, 681-691.	1.8	31

#	Article	IF	Citations
73	Use of the single-strand conformation polymorphism technique to detect loss of heterozygosity in neuroblastoma. Genes Chromosomes and Cancer, 1993, 7, 102-108.	2.8	29
74	Autoregulation of the human N-myc oncogene is disrupted in amplified but not single-copy neuroblastoma cell lines. Oncogene, 1997, 15, 1937-1946.	5.9	29
75	The Future of Surveillance in the Context of Cancer Predisposition: Through the Murky Looking Glass. Clinical Cancer Research, 2017, 23, e133-e137.	7.0	29
76	p75 mediated apoptosis in neuroblastoma cells is inhibited by expression of TrkA. Medical and Pediatric Oncology, 2000, 35, 573-576.	1.0	27
77	The effect of P75 on Trk receptors in neuroblastomas. Cancer Letters, 2011, 305, 76-85.	7.2	27
78	Molecular characterization and chromosomal localization of DRT (EPHT3): a developmentally regulated human protein--tyrosine kinase gene of the EPH family. Human Molecular Genetics, 1995, 4, 2033-2045.	2.9	26
79	Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. Medical and Pediatric Oncology, 2000, 35, 526-530.	1.0	26
80	Phenotypic Differences in Juvenile Polyposis Syndrome With or Without a Disease-causing SMAD4/BMPR1A Variant. Cancer Prevention Research, 2021, 14, 215-222.	1.5	26
81	Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomas. Medical and Pediatric Oncology, 2000, 35, 512-515.	1.0	25
82	Prognostic significance ofEPHB6, EFNB2, andEFNB3 expressions in neuroblastoma. Medical and Pediatric Oncology, 2000, 35, 656-658.	1.0	25
83	Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model. Clinical Cancer Research, 2018, 24, 2585-2593.	7.0	25
84	The effectiveness of Wilms tumor screening in Beckwithâ€“Wiedemann spectrum. Journal of Cancer Research and Clinical Oncology, 2019, 145, 3115-3123.	2.5	25
85	MYCN Is the only highly expressed gene from the core amplified domain in human neuroblastomas. Genes Chromosomes and Cancer, 1998, 23, 134-140.	2.8	22
86	AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts. Cancer Chemotherapy and Pharmacology, 2012, 70, 477-486.	2.3	22
87	Management of adrenal masses in patients with Beckwithâ€“Wiedemann syndrome. Pediatric Blood and Cancer, 2017, 64, e26432.	1.5	22
88	Retinoic acid-induced CHD5 upregulation and neuronal differentiation of neuroblastoma. Molecular Cancer, 2015, 14, 150.	19.2	21
89	Role of microRNAs in epigenetic silencing of the CHD5 tumor suppressor gene in neuroblastomas. Oncotarget, 2016, 7, 15977-15985.	1.8	20
90	Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatric Blood and Cancer, 2019, 66, e27819.	1.5	20

#	Article	IF	Citations
91	Association amongEPHB2, TrkA, andMYCN expression in low-stage neuroblastomas. Medical and Pediatric Oncology, 2001, 36, 80-82.	1.0	19
92	Development of subnanomolar radiofluorinated (2-pyrrolidin-1-yl)imidazo[1,2-b]pyridazine pan-Trk inhibitors as candidate PET imaging probes. MedChemComm, 2015, 6, 2184-2193.	3.4	19
93	Earlier Colorectal Cancer Screening May Be Necessary In Patients With Li-Fraumeni Syndrome. Gastroenterology, 2019, 156, 273-274.	1.3	19
94	Significance of intratumoral genetic heterogeneity in neuroblastomas. Medical and Pediatric Oncology, 2002, 38, 112-113.	1.0	18
95	Different effects of TrkA expression in neuroblastoma cell lines with or withoutMYCN amplification. Medical and Pediatric Oncology, 2000, 35, 623-627.	1.0	17
96	Analysis of genomic imprinting at 1p35-36 in neuroblastoma. Medical and Pediatric Oncology, 2001, 36, 52-55.	1.0	16
97	Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma. Cancer Chemotherapy and Pharmacology, 2011, 68, 1469-1475.	2.3	16
98	Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model. Molecular Cancer Therapeutics, 2020, 19, 920-926.	4.1	15
99	Biological aspects of neuroblastoma screening. Medical and Pediatric Oncology, 1998, 31, 394-400.	1.0	14
100	A Novel Nanomicellar Combination of Fenretinide and Lenalidomide Shows Marked Antitumor Activity in a Neuroblastoma Xenograft Model . Drug Design, Development and Therapy, 2019, Volume 13, 4305-4319.	4.3	13
101	TrkA signal transduction pathways in neuroblastoma. Medical and Pediatric Oncology, 2001, 36, 108-110.	1.0	11
102	Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors.. Journal of Clinical Oncology, 2018, 36, 10536-10536.	1.6	10
103	A variant transcript encoding an isoform of the human protein tyrosine kinase EPHB2 is generated by alternative splicing and alternative use of polyadenylation signals. Oncogene, 1998, 17, 521-526.	5.9	9
104	Gain-of-Function STAT1 Mutation With Familial Lymphadenopathy and Hodgkin Lymphoma. Frontiers in Pediatrics, 2019, 7, 160.	1.9	9
105	Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors. Cancer Research, 2020, 80, 4258-4265.	0.9	9
106	Biology of tumors of the peripheral nervous system. Cancer and Metastasis Reviews, 1991, 10, 321-333.	5.9	8
107	Do the ends justify the means?. Nature Medicine, 1995, 1, 203-205.	30.7	8
108	Rotary bioreactor culture can discern specific behavior phenotypes in Trk-null and Trk-expressing neuroblastoma cell lines. In Vitro Cellular and Developmental Biology - Animal, 2014, 50, 188-193.	1.5	8

#	Article	IF	Citations
109	Schwann cell-conditioned medium inhibits angiogenesis in vitro and in vivo. Medical and Pediatric Oncology, 2000, 35, 590-592.	1.0	6
110	Pediatric Somatic Tumor Sequencing Identifies Underlying Cancer Predisposition. JCO Precision Oncology, 2019, 3, 1-26.	3.0	6
111	The Clinical Spectrum of PTEN Hamartoma Tumor Syndrome: Exploring the Value of Thyroid Surveillance. Hormone Research in Paediatrics, 2020, 93, 634-642.	1.8	6
112	RET receptor expression and interaction with TRK receptors in neuroblastomas. Oncology Reports, 2020, 44, 263-272.	2.6	6
113	Getting Into the AKT. Journal of the National Cancer Institute, 2010, 102, 747-749.	6.3	5
114	Poloxamerâ€linked prodrug of a topoisomerase I inhibitor SN22 shows efficacy in models of highâ€risk neuroblastoma with primary and acquired chemoresistance. FASEB Journal, 2022, 36, e22213.	0.5	5
115	Knowing Your ABCCs: Novel Functions of ABCC Transporters. Journal of the National Cancer Institute, 2011, 103, 1207-1208.	6.3	4
116	Nanomicellar Lenalidomideâ€“Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor . International Journal of Nanomedicine, 2020, Volume 15, 6873-6886.	6.7	4
117	Environment-Sensitive Polymeric Micelles Encapsulating SN-38 Potently Suppress Growth of Neuroblastoma Cells Exhibiting Intrinsic and Acquired Drug Resistance. ACS Pharmacology and Translational Science, 2021, 4, 240-247.	4.9	4
118	Molecular Analysis of Gene Amplification in Tumors. Current Protocols in Human Genetics, 1994, 2, Unit 10.5.	3.5	3
119	Role of Apoptosis in Human Neuroblastomas. , 1999, , 305-318.		3
120	Nanocarrier-Based Delivery of SN22 as a Tocopheryl Oxamate Prodrug Achieves Rapid Tumor Regression and Extends Survival in High-Risk Neuroblastoma Models. International Journal of Molecular Sciences, 2022, 23, 1752.	4.1	3
121	p75 mediated apoptosis in neuroblastoma cells is inhibited by expression of TrkA. Medical and Pediatric Oncology, 2000, 35, 573-576.	1.0	2
122	Biological aspects of neuroblastoma screening. Medical and Pediatric Oncology, 1998, 31, 394-400.	1.0	1
123	Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors. , 2001, 92, 2699.		1
124	Significance of intratumoral genetic heterogeneity in neuroblastomas. Medical and Pediatric Oncology, 2002, 38, 112.	1.0	1
125	Identifying TRKA and TRKB specific pathways in neuroblastoma through phosphoproteomic analysis.. Journal of Clinical Oncology, 2012, 30, e20008-e20008.	1.6	0
126	Colorectal cancer risk in Li-Fraumeni syndrome: Is it time for earlier surveillance?. Journal of Clinical Oncology, 2018, 36, e13503-e13503.	1.6	0

#	Article	IF	Citations
127	Abstract 5898: Bone morphogenic protein receptor 2 (BMPR2) as a potential germline driver in Juvenile Polyposis Syndrome (JPS). Cancer Research, 2022, 82, 5898-5898.	0.9	0